ClinicalTrials.gg
RecruitingNCT07090057Plantaris SxUpdated Mar 12, 2026

The Effect of Targeting the Plantaris Muscle-tendon in Surgical Correction of Ankle Equinus in Children

An interventional study of Tendoachilles (TA) lengthening or gastrocnemius (GN) recession, then Plantaris tenotomy and Plantaris tenotomy, then Tendoachilles (TA) lengthening or gastrocnemius (GN) recession in Idiopathic Toe Walking, Cerebral Palsy and Hereditary Spastic Paraparesis, sponsored by University of Alberta. Recruiting at 1 site in Canada. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by University of Alberta · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 4 months after the study started (first participant enrolled Mar 2023, registered Jul 2025).
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
4 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 82 studies in Cerebral Palsy with a site in Canada — 26 open to participants now, 27 under way, none of them phase 3. Cerebral Palsy · Canada.

Planned enrollment
27th of 69
42 · median 26
Started
2023
with 6 others
No phase
58 of 82
20 open now
Primary completion
2026-12
later than 12 of 26 live
Registered
76th of 82
by date
Lead sponsor
8 of 82
University of Alberta

Among the 82 studies in Cerebral Palsy with a site in Canada, this one is the 27th largest by planned enrollment of the 69 interventional ones that give a count, is one of 7 that started in 2023, is one of 58 with no phase, reaches primary completion later than 12 of the 26 other live ones, and was the 76th registered.

Cerebral Palsy

1,942 studies on the registry are indexed under Cerebral Palsy; 456 are open to participants now.

Browse Cerebral Palsy studies →

Open to participants now

26 of the 82 studies in Cerebral Palsy with a site in Canada are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 271 Cerebral Palsy studies recruiting now, 26 (10%) set no upper age limit and 237 (87%) stop at 75 or younger; 256 take children under 18; 53 take healthy volunteers.

This study: 4 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Cerebral Palsy with a site in Canada, or all of them as a file.
02

Study summary

Tight ankle muscles can produce ankle equinus (limited ability to pull the foot upward) and occur often in children, significantly impacting their ability to walk. If not treated, children with ankle equinus frequently experience reduced function and long-term foot problems, such as pain. Currently, treatment options include surgery or Botulinum toxin (BoNTA) injection into the large calf muscles that point the foot downwards, aiming to reduce their tightness. However, these treatments can be less effective over time, can create prolonged calf weakness, and may require long-term bracing. Another small muscle in the leg, the plantaris, is believed to have some contribution to equinus in many children. It is sometimes included in treatment plans for equinus but its contribution is poorly understood. It is unclear whether targeting the plantaris alone could lead to better treatment of ankle equinus. Understanding the effect of treatments targeting the plantaris could help clinicians improve the management of ankle equinus.

In this study, the investigators will look at the impact of surgical treatment to the plantaris in ankle equinus. The investigators hypothesize that the plantaris is a significant contributor to equinus.

In this study, data will be collected from children undergoing surgical correction of ankle equinus, including lengthening of the plantaris and lengthening of the larger muscles producing equinus (the gastrocsoleus mechanism). Children will be randomly assigned to have either their plantaris or the gastrocsoleus lengthening be done first during surgery. All children will have both structures lengthened during surgery, only the order will be varied and all surgical procedures for each patient will be completed in a single setting. In both groups, maximum passive ankle dorsiflexion (upwards bend of the ankle with the knee straight) will be measured before and after each structure is lengthened. The outcome is maximum passive ankle dorsiflexion (upwards bend of the ankle) with the knee straight.

The investigators expect that maximum passive ankle dorsiflexion will increase after lengthening of the plantaris. Understanding the contribution of the plantaris muscle in ankle equinus could lead to significant improvements in the treatment of children with tight ankles.

Read the detailed description

Children demonstrating equinus gait, characterized as \<10° of ankle dorsiflexion relative to the leg, are commonly referred for specialist assessment. Equinus gait or deformity can occur in isolation (e.g. idiopathic toe-walking), with other foot deformities (e.g. clubfoot), or with underlying neuromotor conditions (e.g. cerebral palsy). A 2019 study found 83.3% of patients surveyed with cerebral palsy had equinus.

In children with underlying spasticity and no significant contracture, chemodenervation via Botulinum toxin (BoNTA) injections of the gastroc-soleus (GS) complex is often used to maintain functional range and optimize gait. Typically, injections become less effective over time, often leading to equinus contracture, functional impairment, and the need for orthoses or surgery. Once surgical intervention (i.e. tendoachilles (TA) lengthening or gastrocnemius (GN) recession) is required, contracture of the plantaris muscle has also been noted, usually requiring concomitant or later lengthening via tenotomy. Surgical GS lengthenings to treat ankle equinus can result in prolonged and sometimes incomplete recovery of ankle plantarflexion strength despite intensive physiotherapy, adversely affecting gait and lower limb function.

The presence and course of plantaris are believed to be variable. Recent evidence indicates that it is present in 98-100% of the population while historical estimates ranged from 80-93%. Historically considered a vestigial structure with no significant functional impact, more recently, plantaris contraction is considered to impact knee flexion and ankle plantarflexion as well as possibly contribute to external rotation of the lower leg and hindfoot inversion, similar to the GN. Given these potential functional similarities and empiric intra-operative observations of improved ankle dorsiflexion with plantaris lengthening in addition to GS complex lengthening, a plantaris tenotomy is often performed during surgery for equinus contracture. However, clinical recognition of the plantaris contribution to equinus gait and/or contracture remains inconsistent, and the effect of treatments targeting the plantaris are not well described in the literature.

The overall goal of this proposed study is to examine the contribution of the plantaris to ankle equinus by assessing the short-term impact of surgical treatment targeting the plantaris muscle-tendon unit to manage children with equinus gait and/or contracture.

The trial will compare changes to passive ankle dorsiflexion after plantaris tenotomy performed either a) before TA lengthening or GN recession or b) after TA lengthening or GN recession (in a single surgical encounter).

If this surgical trial finds that plantaris significantly contributes to equinus contracture, it may support using exclusively open surgical techniques (rather than percutaneous), so the plantaris can be identified and addressed adequately. In addition, if the effect of plantaris is significant, it is possible that early isolated release of the plantaris tendon may be a treatment option while preserving the gastrocsoleus complex and thereby reducing post-operative weakness. This approach would benefit from the development of minimally invasive techniques to identify the tendon but has the potential reduce the long-term requirement for Achilles tendon lengthening with improved preservation of plantarflexion strength by reducing the feedback mechanism from the plantaris to the gastrocsoleus complex.

The investigators hypothesize that the plantaris significantly contributes to equinus contracture in children and that plantaris tenotomy in this population significantly improves passive ankle dorsiflexion, independent of the GS mechanism.

The primary objectives of this study are to:

1) Compare the effect of plantaris tenotomy in the setting of equinus contracture on passive ankle dorsiflexion relative to that of TA lengthening or GN recession.

The secondary objectives are to:

  1. Quantify the proportion of participants with an identifiable plantaris
  2. Describe the location of the insertion of the plantaris tendon in those with an identified plantaris

This is a single-centre, randomized intra-operative clinical study involving pediatric patients undergoing surgery for equinus contracture at the Stollery Children's Hospital. All procedures will occur within a single operative session and will be performed by pediatric orthopedic surgeons. Pre- and post-intervention assessments will be performed intra-operatively, so minimal loss to follow-up is expected. Maximum passive ankle dorsiflexion will be measured by the surgeon with a sterile goniometer at four different time points (before and after lengthening of each tendon/aponeurosis), with the knee maximally extended. To minimize confounding by any co-existing intrinsic foot deformities, ankle dorsiflexion will be measured with the long axis of the leg and long axis of the heel pad as the points of reference.

After both structures (i.e., plantaris tendon and GN aponeurosis or Achilles tendon) have been identified, the plantaris location will be documented. In GN recession cases where there is inadequate dorsiflexion after both procedures, the surgeon may complete a partial lengthening of the soleus at their discretion, with a fifth set of measurements documented after completion.

The study population will include children undergoing surgical lengthening of the GN or TA. 42 participants (21 per group, 20 for power and one in case a patient doesn't have a plantaris or whose physical examination changes between consent and surgery) will be included.

Due to the paucity of literature, estimate of required sample size is based on a minimal clinically important difference (MCID) derived from the experience of the study surgeons. There were 27 and 28 eligible patients in 2020 and 2021 respectively.

A member of the patient's care team (i.e. surgeon, nurse, or resident) will identify potential participants, completing a Consent to Contact from when patients are consented or scheduled for the index procedure. A Research Associate will contact the potential participant or their legal guardian and explain the study. If the potential participants wish to take part, they will provide consent via e-consent on REDCap. Once consent is obtained, notification will be sent to the treating surgeons' office, along with the participant's randomization allocation.

A computer-generated, uneven block randomization sequence will be used to randomize participants to one of the two groups.

Descriptive statistics will characterize baseline demographics and any systematic differences among groups will be risk-adjusted. Maximum passive ankle dorsiflexion during surgery will be examined using ANOVA or corresponding Kruskal-Wallis model.

Summary:

Surgery is routinely done for patients with equinus contracture involving lengthening of the tendoachilles or gastrocnemius and then plantaris to achieve the desired ankle range of motion. In this study, the investigators want to understand the contribution of plantaris to ankle equinus in children. In the future, if plantaris can be cut first and the desired range of motion is obtained, then the tendoachilles and gastrocnemius need not be cut. This will dramatically reduce post-operative recovery time and will likely preserve ankle plantarflexor strength.

03

Conditions studied

  • Idiopathic Toe Walking
  • Cerebral Palsy
  • Hereditary Spastic Paraparesis
  • Traumatic Brain Injury
  • Spinal Cord Injury
  • Spinal Cord Tethering
  • Stroke
  • Hereditary Sensory-motor Neuropathy

Keywords

  • tendoachilles lengthening
  • gastrocnemius recession
  • Plantaris lengthening
04

Who can participate

Ages eligible
4 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (All of the following criteria must be met):

  • Ability to provided /assent in English.
  • Pediatric patients (4-17 years) who have consented for surgery for the management of equinus contracture * (either TA lengthening or GN recession) at the Stollery Children's Hospital
  • Known underlying diagnosis of any of the following: idiopathic toe walking, cerebral palsy, hereditary spastic paraparesis, traumatic brain injury, spinal cord injury/tethering, hereditary sensory-motor neuropathy, stroke
  • Ability to maintain hindfoot and midfoot neutral during assessment
  • Passive plantarflexion on affected side greater than 20° and greater than degree of equinus contracture.

    • Note: may be isolated or in conjunction with other orthopaedic procedures; in bilateral ankle equinus procedures, data will be collected bilaterally, but included as a single participant (i.e., single randomization).

Exclusion Criteria (Any one or more of the following):

  • Unable to provide informed consent/assent in English.
  • Previous surgery for equinus
  • Limb deficiency on affected side
  • Knee flexion contracture of greater than 5°
  • Surgical intervention of the lower extremities below the affected knee in the last twelve months
  • BoNTA injections below the affected knee within the last six months
  • Known or suspected arthrofibrosis.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Tendoachilles (TA) lengthening or gastrocnemius (GN) recession, then Plantaris tenotomy

    Participants undergo Tendoachilles (TA) lengthening or gastrocnemius (GN) recession surgery before Plantaris tenotomy.

    Procedure: Tendoachilles (TA) lengthening or gastrocnemius (GN) recession, then Plantaris tenotomy

  • Experimental
    Plantaris tenotomy, then Tendoachilles (TA) lengthening or gastrocnemius (GN) recession

    Participants undergo Plantaris tenotomy surgery before Tendoachilles (TA) lengthening or gastrocnemius (GN) recession.

    Procedure: Plantaris tenotomy, then Tendoachilles (TA) lengthening or gastrocnemius (GN) recession

Interventions

  • ProcedureTendoachilles (TA) lengthening or gastrocnemius (GN) recession, then Plantaris tenotomy

    Participants undergo Tendoachilles (TA) lengthening or gastrocnemius (GN) recession surgery before Plantaris tenotomy.

  • ProcedurePlantaris tenotomy, then Tendoachilles (TA) lengthening or gastrocnemius (GN) recession

    Participants undergo plantaris tenotomy surgery before Tendoachilles (TA) lengthening or gastrocnemius (GN) recession.

06

What researchers measure

Primary outcomes

  1. Maximum passive ankle dorsiflexion

    Ankle dorsiflexion (unit: degree) will be measured by the surgeon with a sterile goniometer during the surgery.

    Time frame: Prior to skin incision

  2. Maximum passive ankle dorsiflexion

    Ankle dorsiflexion (unit: degree) will be measured by the surgeon with a sterile goniometer during the surgery.

    Time frame: Prior to division of first tendon/aponeurosis

  3. Maximum passive ankle dorsiflexion

    Ankle dorsiflexion (unit: degree) will be measured by the surgeon with a sterile goniometer during the surgery.

    Time frame: After division of first tendon/aponeurosis

  4. Maximum passive ankle dorsiflexion

    Ankle dorsiflexion (unit: degree) will be measured by the surgeon with a sterile goniometer during the surgery.

    Time frame: After division of second tendon/aponeurosis

07

Study locations

1 of 1 sites recruiting
  • Stollery Children's Hospital
    Edmonton, Alberta T6G2B7, Canada
    Recruiting
    • Sukhdeep Dulai, MD, MHSc, FRCSC · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Dec 2026, 45 months after the start.

Of 906 non-industry interventional studies with no phase under Cerebral Palsy, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 31. This study's planned 45 months is above that.

Counting every sponsor, half of 925 studies reached it within 12 months; a quarter within 5 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2025
First posted
Jul 29, 2025
StartActual
Mar 13, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07090057
Responsible party
Sponsor
First posted
Jul 29, 2025
Start date
Mar 13, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 12, 2026

Study contacts

Ailar Ramadi, PhD
Contact
Ailar.Ramadi@albertahealthservices.ca
780-492-2398
Collaborative Orthopaedic Research (CORe)
Contact
frmcore1@ualberta.ca
Sukhdeep Dulai, MD, MHSc, FRCSC
principal investigator · University of Alberta

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion